Google, care.ai join forces to build safer hospital rooms

Google and care.ai have announced a new partnership focused on bringing autonomous monitoring technology to hospitals environments.

The collaboration involves care.ai’s autonomous monitoring platform and Google’s Coral Edge TPU. Traditional hospital rooms will be outfitted with AI-powered sensors that can send “context-aware, intelligent notifications" to hospital employees at times when a preventable accident or medical error is about to take place. The neural networks learn as they operate, evolving to make the rooms safer for patients as time goes on.  

“Imagine if we brought the power of AI with autonomous monitoring to healthcare environments—we could prevent injuries, diseases, protocol breaches, and ultimately fatalities; while improving staff efficiency,” Chakri Toleti, founder and CEO of care.ai, said in a prepared statement. “By utilizing Google’s Edge TPU, care.ai has done just that—we have built an AI sensor to monitor, predict, and infer behaviors using billions of data points in real time. It is truly the world’s most advanced AI platform for healthcare.”

“We believe we are on the cusp of an amazing revolution for AI in healthcare and are proud to partner with care.ai to witness it becoming a reality,” Billy Rutledge, director of the Coral platform for Google, said in the same statement.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.